• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vertex Pharmaceuticals (NQ:VRTX)

    520.54 -0.58 (-0.11%)
    Streaming Delayed Price Updated: 10:25 AM EDT, Sep 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vertex Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    76 77 Next >
    News headline image
    Vertex Pharmaceuticals Q2 Earnings Call Highlights ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations
    Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. ... 
    Via StockStory
    News headline image
    Vertex Reports Second Quarter 2026 Financial Results
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For
    Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for. Vertex Pharmaceuticals be... 
    Via StockStory
    Topics Artificial Intelligence
    Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout ↗
    Via Chartmill
    Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation ↗
    Via Chartmill
    News headline image
    Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗
    There are other reasons to pay attention to Viking Therapeutics. 
    Via The Motley Fool
    News headline image
    Morgan Stanley Nearly Doubled Its Price Target for CRISPR Therapeutics. Is the Gene-Editing Stock a No-Brainer Buy? ↗
    The next six months may be decisive for the biotech. 
    Via The Motley Fool
    News headline image
    AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    3 Healthcare Stocks with Competitive Advantages
    From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
    Via StockStory
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq – TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq – CRNX), Element Solutions Inc. (NYSE – ESI)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching ↗
    The biotech's diversification efforts continue. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question
    The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ... 
    Via StockStory
    News headline image
    $1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals... 
    Via Benzinga
    News headline image
    Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals ↗
    Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be. 
    Via The Motley Fool
    News headline image
    Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? ↗
    Vertex Pharmaceuticals recently announced its largest-ever acquisition. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse ↗
    Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a... 
    Via MarketBeat
    News headline image
    Is This Biotech Stock a Buy Near Its 52-Week High? ↗
    It's been a volatile year for the company, but don't let that scare you away. 
    Via The Motley Fool
    News headline image
    Why This Pharmaceutical Stock Jumped Close to 100% This Week ↗
    It is getting acquired by a larger firm in the sector. 
    Via The Motley Fool
    Topics Bonds
    News headline image
    3 Reasons to Buy CRISPR Therapeutics Stock ↗
    The company's innovative qualities may pay rich dividends down the road. 
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy? ↗
    Additional blockbuster drugs may be on the horizon. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    1 Momentum Stock to Research Further and 2 Facing Headwinds
    Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such a... 
    Via StockStory
    News headline image
    Vertex’s Crinetics Deal Balances Growth with Integration Risk ↗
    Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis... 
    Via MarketBeat
    News headline image
    A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
    This new technology could one day significantly expand the market for gene-editing biotechs. 
    Via The Motley Fool
    News headline image
    Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. ↗
    This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate. 
    Via The Motley Fool
    News headline image
    Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. ↗
    The drugmaker is paying up for a new growth engine. Is the price disciplined? 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
    From Vertex Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    3 Cash-Heavy Stocks with Promising Prospects
    In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for t... 
    Via StockStory
    Which S&P500 stocks are showing activity after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Vertex to Acquire Crinetics Pharmaceuticals
    From Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    76 77 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.